Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 7/20 | 0.64 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | CHRND | Q07001 | 6/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.47 |
| ▸ | CHRNG | P07510 | 2/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16589714 | 0.89 | GRIA1 (0.51) | GRIA1CTSSCTSKKIFC1CTSL | |
| SCHEMBL20866078 | 0.86 | GRIA1 (0.68) | GRIA1CTSSCTSKCHRNDCHRNA1 | |
| SCHEMBL16589721 | 0.85 | GRIA1 (0.77) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL15359366 | 0.83 | GRIA1 (0.46) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL16589702 | 0.78 | GRIA1 (0.40) | GRIA1KIFC1 | |
| SCHEMBL14032602 | 0.78 | CYP3A4 (0.52) | — | |
| SCHEMBL2550705 | 0.77 | FOLH1 (0.61) | GRIA1 | |
| SCHEMBL2550703 | 0.77 | FOLH1 (0.61) | GRIA1 | |
| SCHEMBL16589717 | 0.77 | KDM4E (0.37) | GRIA1AVPR1AKIFC1 | |
| SCHEMBL16589716 | 0.76 | KDM4E (0.36) | GRIA1AVPR1AKIFC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ABCB1, CYP2D6, LDHA | GRIA1 3272/4885CTSS 1210/4885CTSK 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.